To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Inclusion Criteria: * Weight of \> 40 kilograms (kg) and \< 120 kg at Screening. * In good general health, determined by no clinically significant findings in the opinion of the Investigator from medical history, physical examination, 12-lead ECG, clinical laboratory findings, and vital signs at Screening and Check-in. * Hemoglobin, hematocrit, white blood cell count, absolute neutrophil count, and platelet count results within the normal range at the Screening Visit; participants with Gilbert's disease with associated abnormalities of liver function tests are eligible for enrollment. Tests may be repeated at the discretion of the Investigator to confirm abnormalities. * Creatinine clearance based on the Cockcroft-Gault equation of \>= 80 milliliters per minute (ml/min). * Females of childbearing potential and males must practice effective contraception from Screening until 28 days after the end of study (EOS) visit. * Females of childbearing potential must have a negative pregnancy test at Screening and within 24 hours prior to dosing of study drug; for post-menopausal subjects, a blood sample will also be tested for follicle stimulating hormone to confirm post-menopausal status. Exclusion Criteria: * Any clinically significant underlying illness in the opinion of the Investigator. * Any history or sign of significant chronic active or recurrent infection, or screening laboratory evidence consistent with a significant chronic active or recurrent infection requiring treatment with antibacterials, antivirals, or antifungals. * Treatment of any infection with IV (within 30 days of Screening) or oral (within 14 days of Screening) antibacterials, antivirals, or antifungals. * History of clinically significant hematologic or bone marrow disease or blood dyscrasias. * History of meningococcal infection. * History of tuberculosis. * History of asplenia (functional or anatomical). * Prior exposure to KP104. * Known allergy to penicillin antibiotics or history of allergy or contraindication to required prophylactic antibiotic therapy to be used during the study. * Known or suspected complement deficiency during screening. * Positive serology for Hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) at Screening. * History of drug or alcohol abuse within 1 year of Screening in the opinion of the investigator, or a positive test for drugs of abuse or alcohol at Screening or Check-in. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.